Disposition of total and unbound etoposide following high-dose therapy

[1]  W. Evans,et al.  Factors affecting in vitro protein binding of etoposide in humans. , 1992, Journal of pharmaceutical sciences.

[2]  M. Relling,et al.  Increased teniposide clearance with concomitant anticonvulsant therapy. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  W. Evans,et al.  Relation of systemic exposure to unbound etoposide and hematologic toxicity , 1991, Clinical pharmacology and therapeutics.

[4]  R. Shadduck,et al.  Autologous bone marrow transplantation following high-dose busulfan and VP-16 for advanced non-Hodgkin's lymphoma and Hodgkin's disease. , 1991, Experimental hematology.

[5]  C. Stewart,et al.  High-Performance Liquid Chromatographic Determination of Etoposide in Plasma , 1991 .

[6]  W. Evans,et al.  Changes in the clearance of total and unbound etoposide in patients with liver dysfunction. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  R L Nation,et al.  Pharmacokinetic Drug Interactions with Phenytoin (Part II) , 1990, Clinical pharmacokinetics.

[8]  R. Milne,et al.  Pharmacokinetic Drug Interactions with Phenytoin (Part I) , 1990 .

[9]  A. Grigg,et al.  Busulphan and phenytoin. , 1989, Annals of internal medicine.

[10]  W. Evans,et al.  Altered protein binding of etoposide in patients with cancer , 1989, Clinical pharmacology and therapeutics.

[11]  J. Doroshow,et al.  Pharmacokinetics of high‐dose etoposide , 1988, Clinical pharmacology and therapeutics.

[12]  W. Evans,et al.  Clinical pharmacodynamics of continuous infusion teniposide: systemic exposure as a determinant of response in a phase I trial. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  J. Doroshow,et al.  Total body irradiation and high-dose etoposide: a new preparatory regimen for bone marrow transplantation in patients with advanced hematologic malignancies [published erratum appears in Blood 1987 Jun;69(6):1789] , 1987 .

[14]  D. Findley,et al.  Total body irradiation and high-dose etoposide: a new preparatory regimen for bone marrow transplantation in patients with advanced hematologic malignancies. , 1987, Blood.

[15]  W. Evans,et al.  Etoposide pharmacokinetics in patients with normal and abnormal organ function. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  N. Mulder,et al.  Pharmacokinetics of high dose etoposide (VP 16-213). , 1986, European journal of cancer & clinical oncology.

[17]  D. P. Bentley,et al.  The effect of etoposide on human CFU-GM. , 1985, British Journal of Cancer.

[18]  Tw. Rall,et al.  Drugs effective in the therapy of the epilepsies , 1985 .

[19]  J. Goldman,et al.  CONVULSIONS DUE TO HIGH-DOSE BUSULPHAN , 1984, The Lancet.

[20]  S. Jagannath,et al.  The role of autologous bone marrow transplantation in various malignancies. , 1984, Seminars in hematology.

[21]  W. Evans,et al.  High-performance liquid chromatographic analysis of the semisynthetic epipodophyllotoxins teniposide and etoposide using electrochemical detection. , 1984, Journal of pharmaceutical sciences.

[22]  G R Wilkinson,et al.  Pharmacokinetics of high-dose etoposide (VP-16-213) administered to cancer patients. , 1984, Cancer research.

[23]  J. Huang.  Errors in estimating the unbound fraction of drugs due to the volume shift in equilibrium dialysis. , 1983, Journal of Pharmacy and Science.

[24]  M. Ehrnebo,et al.  Busulfan kinetics , 1983, Clinical pharmacology and therapeutics.

[25]  C. Tschanz,et al.  Importance of radiochemical purity of radiolabeled drugs used for determining plasma protein binding of drugs. , 1981, Journal of pharmaceutical sciences.